Quarterly ResultAug 10, 2026, 04:13 PM
Olema Completes OPERA-01 Enrollment; Q1 2027 Data; Bayer Deal
AI Summary
Olema Pharmaceuticals reported its Q2 2026 financial and operating results, highlighting significant progress in its clinical pipeline. The company completed enrollment in its pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data anticipated in Q1 2027. Additionally, Olema presented initial Phase 1 clinical data for OP-3136 and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. For the second quarter, Olema reported a net loss of $63.2 million and maintained a strong cash position of $461.1 million.
Key Highlights
- Completed enrollment in pivotal Phase 3 OPERA-01 trial for palazestrant.
- Top-line data from OPERA-01 trial now expected in Q1 2027.
- Announced clinical trial collaboration with Bayer for OP-3136.
- Presented initial Phase 1 clinical data for OP-3136.
- Q2 2026 net loss was $63.2 million, up from $43.8 million YoY.
- Q2 2026 R&D expenses were $57.8 million, up from $43.9 million YoY.
- Ended Q2 2026 with $461.1 million in cash, cash equivalents, and marketable securities.
Price Impact
More from OLMA